NextCure, Inc.
NXTC
$12.15
-$0.40-3.19%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -12.25% | -14.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -67.22% | 134.83% | |||
| Operating Income | 67.22% | -134.83% | |||
| Income Before Tax | 67.83% | -144.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 67.83% | -144.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 67.83% | -144.24% | |||
| EBIT | 67.22% | -134.83% | |||
| EBITDA | 68.45% | -143.06% | |||
| EPS Basic | 71.45% | -140.04% | |||
| Normalized Basic EPS | 71.45% | -140.04% | |||
| EPS Diluted | 71.45% | -140.04% | |||
| Normalized Diluted EPS | 71.45% | -140.04% | |||
| Average Basic Shares Outstanding | 12.69% | 1.75% | |||
| Average Diluted Shares Outstanding | 12.69% | 1.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||